Home › NDC Lookup › RxCUI directory › RxCUI 637550

Topotecan 4 MG Injection [Hycamtin] — RxCUI 637550

RxNorm drug concept · Semantic branded drug
RxCUI 637550 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI637550
Official nameTopotecan 4 MG Injection [Hycamtin]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asHycamtin 4 MG Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Topotecan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Topotecan is a chemotherapy used for three types of cancer: small cell lung cancer (SCLC), metastatic ovarian cancer, and advanced cervical cancer. The IV form covers all three, de...
  • What exactly is topotecan used to treat?
  • The most common effects are drops in blood counts — low white blood cells, red blood cells, and platelets — along with nausea, vomiting, hair loss, fatigue, and bowel changes. Most...
  • What side effects should I expect, and which ones should make me call someone right away?
📖 Read our full Topotecan guide →

🕸️ Concept Web — How Topotecan 4 MG Injection [Hycamtin] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Topotecan 4 MG Injection [Hycamtin] RxCUI 637550

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Topotecan 57308
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Hycamtin 203472
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Topotecan Injection 1799415
    • Topotecan Injectable Product 1157655
    • Topotecan Injection [Hycamtin] 1799418
    • Hycamtin Injectable Product 1172714
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Topotecan 4 MG Injection SCD · 1799416
  • Topotecan 4 MG SCDC · 1799414
  • Topotecan Injection SCDF · 1799415
  • Topotecan Injectable Product SCDG · 1157655

Brand-Name Concepts

  • Topotecan 4 MG [Hycamtin] SBDC · 1799417
  • Topotecan Injection [Hycamtin] SBDF · 1799418
  • Hycamtin Injectable Product SBDG · 1172714
  • Hycamtin BN · 203472

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 637550 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0674-61 1 VIAL, SINGLE-DOSE in 1 CARTON (0078-0674-61) / 4 mL in 1... HYCAMTIN Novartis Pharmaceuticals Corporation 2016-12-21
Observed labelers: Novartis Pharmaceuticals Corporation (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.